{"id":7053075,"date":"2026-08-31T21:09:12","date_gmt":"2026-08-31T21:09:12","guid":{"rendered":"https:\/\/peraltafinancing.com\/uncategorized\/verrica-completes-enrolment-in-phase-iii-trial-of-ycanth\/"},"modified":"2026-08-31T21:09:12","modified_gmt":"2026-08-31T21:09:12","slug":"verrica-completes-enrolment-in-phase-iii-trial-of-ycanth","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=7053075","title":{"rendered":"Verrica completes enrolment in Phase III trial of Ycanth"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \"\"\/\n <\/picture>
The COVE-2 study is the first of two double-blind, vehicle-controlled, randomised trial assessing the safety and efficacy of VP-102\/TO-208. Credit: PaeGAG \/ Shutterstock.com.<\/figcaption><\/figure>\n<\/p><\/div>\n

Verrica Pharmaceuticals has completed patient enrolment in its first pivotal Phase III trial, COVE-2, which is part of a global clinical programme evaluating Ycanth (VP-102), to treat common warts.<\/p>\n

Top line data from the trial are anticipated in the first quarter of 2027.<\/p>\n

\n
\n
\"\"\/<\/figure>\n

Discover B2B Marketing That Performs <\/h4>\n

\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n


\n\t\t\t\t\t\t\tFind out more <\/svg><\/span><\/a><\/p>\n<\/section>\n<\/div>\n

Conducted in the US, the COVE-2 trial follows a previously completed Phase II trial that had shown a decline in the number of common warts, patients achieving complete clearance, and durability of clearance in many cases.<\/p>\n

It is the first of two double-blind, vehicle-controlled, randomised trials assessing the safety and efficacy of VP-102\/TO-208.<\/p>\n

Both studies are designed to test application of the treatment once every 21 days, for up to four applications, in patients aged two years and older with common warts.<\/p>\n

The company also reported that the second pivotal trial, COVE-3, which is recruiting in both the US and Japan, has already exceeded 50% of its current enrolment target ahead of schedule.<\/p>\n

The interim analysis of COVE-2 was conducted by an independent statistician to assess study power and recommended no need for additional subjects. Verrica Pharmaceuticals remains blinded to the specific data outcomes.<\/p>\n

Verrica president and CEO Jayson Rieger said: \u201cI am very pleased to announce substantial progress in our global Phase III programme seeking to expand the label for Ycanth to include common warts.<\/p>\n

\u201cWe have now completed enrolment in the first pivotal trial, COVE-2, after conducting a per-protocol interim analysis evaluating powering assumptions. The interim analysis confirms that no additional subjects are recommended.\u201d<\/p>\n

The global Phase III programme also includes a supportive long-term follow-up study (COVE-4) and a pharmacokinetics trial (COVE-5).<\/p>\n

Verrica and its Japanese partner, Torii Pharmaceutical plan to seek marketing approval in the US and Japan based on the results from these trials.<\/p>\n

The companies are sharing the costs of the programme, with Torii funding the first $40m, representing approximately 90% of current costs.<\/p>\n

In January 2024, Verrica Pharmaceuticals dosed the last patient in part two of the Phase II trial of VP-315, a new oncolytic peptide immunotherapy for basal cell carcinoma.<\/p>\n

<\/p>\n

<\/p>\n

\n